S&P 500   4,005.62 (+0.07%)
DOW   32,523.89 (-0.11%)
QQQ   312.15 (+0.58%)
AAPL   160.71 (+0.90%)
MSFT   278.30 (+1.65%)
META   204.55 (+1.18%)
GOOGL   105.18 (+0.25%)
AMZN   100.87 (+0.26%)
TSLA   196.70 (-0.45%)
NVDA   272.85 (+4.15%)
NIO   9.32 (+0.54%)
BABA   84.61 (+1.09%)
AMD   100.12 (+4.37%)
T   18.63 (+0.49%)
F   11.78 (+0.51%)
MU   59.42 (+1.35%)
CGC   1.96 (-0.76%)
GE   91.89 (-0.31%)
DIS   96.86 (+0.33%)
AMC   4.54 (+2.95%)
PFE   40.42 (-0.59%)
PYPL   76.00 (-0.94%)
NFLX   301.96 (-1.25%)
S&P 500   4,005.62 (+0.07%)
DOW   32,523.89 (-0.11%)
QQQ   312.15 (+0.58%)
AAPL   160.71 (+0.90%)
MSFT   278.30 (+1.65%)
META   204.55 (+1.18%)
GOOGL   105.18 (+0.25%)
AMZN   100.87 (+0.26%)
TSLA   196.70 (-0.45%)
NVDA   272.85 (+4.15%)
NIO   9.32 (+0.54%)
BABA   84.61 (+1.09%)
AMD   100.12 (+4.37%)
T   18.63 (+0.49%)
F   11.78 (+0.51%)
MU   59.42 (+1.35%)
CGC   1.96 (-0.76%)
GE   91.89 (-0.31%)
DIS   96.86 (+0.33%)
AMC   4.54 (+2.95%)
PFE   40.42 (-0.59%)
PYPL   76.00 (-0.94%)
NFLX   301.96 (-1.25%)
S&P 500   4,005.62 (+0.07%)
DOW   32,523.89 (-0.11%)
QQQ   312.15 (+0.58%)
AAPL   160.71 (+0.90%)
MSFT   278.30 (+1.65%)
META   204.55 (+1.18%)
GOOGL   105.18 (+0.25%)
AMZN   100.87 (+0.26%)
TSLA   196.70 (-0.45%)
NVDA   272.85 (+4.15%)
NIO   9.32 (+0.54%)
BABA   84.61 (+1.09%)
AMD   100.12 (+4.37%)
T   18.63 (+0.49%)
F   11.78 (+0.51%)
MU   59.42 (+1.35%)
CGC   1.96 (-0.76%)
GE   91.89 (-0.31%)
DIS   96.86 (+0.33%)
AMC   4.54 (+2.95%)
PFE   40.42 (-0.59%)
PYPL   76.00 (-0.94%)
NFLX   301.96 (-1.25%)
S&P 500   4,005.62 (+0.07%)
DOW   32,523.89 (-0.11%)
QQQ   312.15 (+0.58%)
AAPL   160.71 (+0.90%)
MSFT   278.30 (+1.65%)
META   204.55 (+1.18%)
GOOGL   105.18 (+0.25%)
AMZN   100.87 (+0.26%)
TSLA   196.70 (-0.45%)
NVDA   272.85 (+4.15%)
NIO   9.32 (+0.54%)
BABA   84.61 (+1.09%)
AMD   100.12 (+4.37%)
T   18.63 (+0.49%)
F   11.78 (+0.51%)
MU   59.42 (+1.35%)
CGC   1.96 (-0.76%)
GE   91.89 (-0.31%)
DIS   96.86 (+0.33%)
AMC   4.54 (+2.95%)
PFE   40.42 (-0.59%)
PYPL   76.00 (-0.94%)
NFLX   301.96 (-1.25%)
NASDAQ:AGEN

Agenus - AGEN Stock Forecast, Price & News

$1.56
-0.08 (-4.60%)
(As of 03/22/2023 02:47 PM ET)
Add
Compare
Today's Range
$1.54
$1.64
50-Day Range
$1.50
$2.95
52-Week Range
$1.25
$3.37
Volume
1.80 million shs
Average Volume
4.81 million shs
Market Capitalization
$517.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.10

Agenus MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
358.2% Upside
$7.10 Price Target
Short Interest
Bearish
6.21% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.93
Upright™ Environmental Score
News Sentiment
0.24mentions of Agenus in the last 14 days
Based on 25 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.87) to ($0.82) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

439th out of 983 stocks

Biological Products, Except Diagnostic Industry

73rd out of 163 stocks


AGEN stock logo

About Agenus (NASDAQ:AGEN) Stock

Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 31, 1994 and is headquartered in Lexington, MA.

Receive AGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agenus and its competitors with MarketBeat's FREE daily newsletter.

AGEN Stock News Headlines

"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
Agenus (NASDAQ:AGEN) Shares Gap Up to $1.71
Agenus (NASDAQ:AGEN) Now Covered by Analysts at StockNews.com
Agenus (AGEN) Set to Announce Quarterly Earnings on Tuesday
Agenus Stock (NASDAQ:AGEN), Dividends
Agenus to Participate in February Investor Conferences
Agenus' Updated Data Confirms Long-Term Potential Value
2 Momentum Trades Showing Worst to First Action
See More Headlines
Receive AGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agenus and its competitors with MarketBeat's FREE daily newsletter.

AGEN Company Calendar

Last Earnings
11/09/2021
Today
3/22/2023
Next Earnings (Estimated)
5/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:AGEN
CUSIP
00847G70
Employees
441
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.10
High Stock Price Forecast
$8.30
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+352.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-220,070,000.00
Net Margins
-235.30%
Pretax Margin
-235.31%

Debt

Sales & Book Value

Annual Sales
$98.02 million
Book Value
($0.18) per share

Miscellaneous

Free Float
316,552,000
Market Cap
$522.04 million
Optionable
Optionable
Beta
1.50

Key Executives

  • Garo H. ArmenGaro H. Armen
    Chairman & Chief Executive Officer
  • Christine M. Klaskin
    Chief Financial & Accounting Officer, VP-Finance
  • Steven O’DaySteven O’Day
    Chief Medical Officer
  • Craig Winter
    Chief Information Officer
  • Alfred Dadson
    Chief Manufacturing Officer













AGEN Stock - Frequently Asked Questions

Should I buy or sell Agenus stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AGEN shares.
View AGEN analyst ratings
or view top-rated stocks.

What is Agenus' stock price forecast for 2023?

3 brokers have issued 12 month price targets for Agenus' stock. Their AGEN share price forecasts range from $5.00 to $8.30. On average, they predict the company's share price to reach $7.10 in the next year. This suggests a possible upside of 352.2% from the stock's current price.
View analysts price targets for AGEN
or view top-rated stocks among Wall Street analysts.

How have AGEN shares performed in 2023?

Agenus' stock was trading at $2.40 at the beginning of 2023. Since then, AGEN stock has decreased by 34.6% and is now trading at $1.57.
View the best growth stocks for 2023 here
.

When is Agenus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our AGEN earnings forecast
.

How were Agenus' earnings last quarter?

Agenus Inc. (NASDAQ:AGEN) announced its quarterly earnings results on Tuesday, November, 9th. The biotechnology company reported $0.69 EPS for the quarter, beating analysts' consensus estimates of $0.46 by $0.23. The biotechnology company had revenue of $252.95 million for the quarter, compared to analyst estimates of $183.11 million. Agenus had a negative net margin of 235.30% and a negative trailing twelve-month return on equity of 1,159.04%. During the same quarter last year, the business posted ($0.28) earnings per share.

What is Garo H. Armen's approval rating as Agenus' CEO?

2 employees have rated Agenus Chief Executive Officer Garo H. Armen on Glassdoor.com. Garo H. Armen has an approval rating of 56% among the company's employees. This puts Garo H. Armen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Agenus own?
What is Agenus' stock symbol?

Agenus trades on the NASDAQ under the ticker symbol "AGEN."

Who are Agenus' major shareholders?

Agenus' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Artal Group S.A. (4.76%), Point72 Asset Management L.P. (2.93%), Geode Capital Management LLC (1.72%), Renaissance Technologies LLC (1.27%), Charles Schwab Investment Management Inc. (0.69%) and Lindbrook Capital LLC (0.44%). Insiders that own company stock include Agenus Inc, Christine M Klaskin, Corp Incyte, Garo H Armen and Steven J O'day.
View institutional ownership trends
.

How do I buy shares of Agenus?

Shares of AGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Agenus' stock price today?

One share of AGEN stock can currently be purchased for approximately $1.57.

How much money does Agenus make?

Agenus (NASDAQ:AGEN) has a market capitalization of $522.04 million and generates $98.02 million in revenue each year. The biotechnology company earns $-220,070,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis.

How many employees does Agenus have?

The company employs 441 workers across the globe.

How can I contact Agenus?

Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The official website for the company is agenusbio.com. The biotechnology company can be reached via phone at (781) 674-4400, via email at investor@agenusbio.com, or via fax at 781-674-4200.

This page (NASDAQ:AGEN) was last updated on 3/22/2023 by MarketBeat.com Staff